Using Computational Disease Models and Synthetic Clinical Trials for Drug Research and Development with David Harel CytoReason TRANSCRIPT
Download PDFJan 9, 2023
David Harel is the Co-Founder and CEO of CytoReason, providing researchers and drug developers with a complex database and predictive computational disease models to conduct synthetic clinical trials. Their mission is to integrate all the information available on a specific disease in a particular population to support faster and more efficient drug development.
David explains, "Computational disease models are the core technology that we've developed, and it is a method to incorporate all the available information, specifically omics and molecular data, that is available in one disease, in one place, in a way that is useful. But people who have been involved in the molecular data space for a while know that the integration of multiple data types and multiple data sets is very difficult, and it needs to be done in a certain context. The context in which we are incorporating the data is allowing the users to run those synthetic trials on their own or using our teams."
"One of the features that we have is the ability to run synthetic basket trials. So, take one drug, assuming the drug you want to evaluate, and run it across multiple indications in these dozens of indications. To conduct that with human subjects is prohibitive for cost and ethical reasons. And the same way, when we are conducting synthetic umbrella trials, where we're taking a specific patient population, and we are evaluating the efficacy of many different compounds in a specific patient population. Again, this would be very difficult to conduct in a clinical setting with human subjects. These are things that synthetic in silico trials allow you to do that clinical endeavors would not."
@CytoReason #DiseaseModels #ComputationalDiseaseModels #SyntheticClinicalTrials #ClinicalTrials #ComputationalBiology #DrugDevelopment #DrugDiscovery #AI #RareDiseases
